Table 2. Serum cytokine profiles and Kruskal-Wallis test between TAFRO-iMCD, iMCD-NOS, and healthy control groups.
| (pg/mL) | IP-10 | PDGF-AA | IL-10 | IL-23 | VEGF-A | IL-13 |
|---|---|---|---|---|---|---|
| TAFRO-iMCD | 507.2 (143.2–2.2 × 103) | 9.2 × 103 (306.7–395 × 103) | 16.5 (3.8–67.3) | 753.9 (0–18834.6) | 2357.1 (281.4–9361.7) | 54.6 (0–138.5) |
| iMCD-NOS | 38.7 (0–221.9) | 245 × 103 (21 × 03–2012 × 103) | 9.5 (7.4–29.6) | 2432.6 (0–8571.5) | 2056.7 (843.1–8801.7) | 113.5 (0–164.8) |
| Healthy controls | 54.0 (22.7–254.5) | 244 × 103 (50 × 103–698 × 103) | 2.4 (0–8.7) | 0 (0–3265.1) | 501.9 (18.1–2007.5) | 68.9 (0–114.8) |
| P < 0.01 | P < 0.01 | P < 0.01 | P < 0.01 | P < 0.01 | P < 0.01 | |
| (pg/mL) | IL-5 | IL-27 | IL-12p70 | IL-1β | IFN-γ | IL-17A |
| TAFRO-iMCD | 0 (0–42.3) | 5.4 (0–112.9) | 12.09 (0–20.2) | 19.2 (0–84.2) | 0 (0–10.6) | 0 (0) |
| iMCD-NOS | 25.7 (0–61.1) | 19.6 (5.9–1718.3) | 15.98 (0–31.0) | 85.7 (0–277.6) | 0 (0–167.8) | 0 (0–1058.7) |
| Healthy controls | 0 (0–55.9) | 0 (0–46.0) | 12.83 (0–14.5) | 36.7 (0–84.2) | 0 (0) | 0 (0) |
| P = 0.03 | P = 0.02 | P = 0.04 | P = 0.05 | NS | NS | |
| (pg/mL) | IL-2 | IL-9 | IL-22 | IL-6 | IL-4 | TNF-α |
| TAFRO-iMCD | 39.2 (11.8–83.9) | 0 (0–20.8) | 0 (0–491.6) | 0 (0–130.7) | 0 (0–14.1) | 14.0 (9.3–387.9) |
| iMCD-NOS | 75.2 (0–396.0) | 2.2 (0–814.4) | 270.8 (0–758.1) | 0 (0–13.8) | 0 (0–102.2) | 30.9 (10.9–61.6) |
| Healthy controls | 35.7 (0–191.2) | 0 (0–228.6) | 160.8 (0–880.1) | 0 (0) | 0 (0–14.6) | 15.7 (7.9–28.8) |
| NS | NS | NS | NS | NS | NS |
IP-10: chemokine interferon γ-induced protein 10 kDa, PDGF-AA: platelet-derived growth factor-AA, IL: interleukin, VEGF-A; vascular endothelial growth factor-A, IFN-γ: interferon-γ, TNF-α: tumor necrosis factor- α, NS: not significant.